keyword
MENU ▼
Read by QxMD icon Read
search

Venom allergy

keyword
https://www.readbyqxmd.com/read/29331065/component-resolved-diagnostics-to-direct-in-venom-immunotherapy-important-steps-towards-precision-medicine
#1
Simon Blank, Maria Beatrice Bilò, Markus Ollert
Stings of Hymenoptera can induce IgE-mediated systemic and even fatal allergic reactions. Venom-specific immunotherapy (VIT) is the only disease-modifying and curative treatment of venom allergy. However, choosing the correct venom for VIT represents a necessary prerequisite for efficient protection against further anaphylactic sting reactions after VIT. In the past, therapeutic decisions based on the measurement of specific IgE (sIgE) levels to whole venom extracts were not always straightforward, especially when the patient was not able to identify the culprit insect...
January 13, 2018: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29322776/altered-serum-metabolite-profiling-and-relevant-pathways-analysis-in-rats-stimulated-by-honeybee-venom-a-new-insight-into-allergy-to-honeybee-venom
#2
Yazhou Zhao, Jianmei Zhang, Yanping Chen, Zhiguo Li, Hongyi Nie, Wenjun Peng, Songkun Su
To improve our understanding of the disturbed metabolic pathways and cellular responses triggered by honeybee venom stimulation, we compared the changes in serum metabolites rats, either stimulated or not by honeybee venom by performing 1H NMR spectrometry-based metabonomics to identify potential biomarkers. In this study, 65 metabolites were structurally confirmed and quantified and the following results were obtained. Firstly, by pattern recognition analysis, 14 metabolites were selected as potential biomarkers 3 hrs after venom stimulation...
January 11, 2018: Journal of Agricultural and Food Chemistry
https://www.readbyqxmd.com/read/29315922/the-use-of-omalizumab-in-allergen-immunotherapy
#3
Jennifer A Dantzer, Robert A Wood
Although omalizumab (anti-IgE) is currently only approved for the treatment of asthma and chronic idiopathic urticaria, it has also been studied as an off-label treatment for numerous allergic conditions, including use as an adjunct to allergen immunotherapy in the treatment of allergic rhinitis, asthma, venom hypersensitivity, and food allergy. We conducted a review of publications involving the use of omalizumab with allergen immunotherapy, by searching PubMed with key search terms of "omalizumab" and "immunotherapy...
January 5, 2018: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29258788/anaphylactic-reactions-after-discontinuation-of-hymenoptera-venom-immunotherapy-a-clonal-mast-cell-disorder-should-be-suspected
#4
Patrizia Bonadonna, Roberta Zanotti, Mauro Pagani, Massimiliano Bonifacio, Luigi Scaffidi, Elisa Olivieri, Maurizio Franchini, Federico Reccardini, Maria Teresa Costantino, Chiara Roncallo, Marina Mauro, Elisa Boni, Fabio Lodi Rizzini, Maria Beatrice Bilò, Anna Rosaria Marcarelli, Giovanni Passalacqua
BACKGROUND: Up to 75% of patients with severe anaphylactic reactions after Hymenoptera sting are at risk of further severe reactions if re-stung. Venom immunotherapy (VIT) is highly effective in protecting individuals with ascertained Hymenoptera venom allergy (HVA) and previous severe reactions. After a 3- to 5-year VIT course, most patients remain protected after VIT discontinuation. Otherwise, a lifelong treatment should be considered in high-risk patients (eg, in mastocytosis). Several case reports evidenced that patients with mastocytosis and HVA, although protected during VIT, can re-experience severe and sometimes fatal reactions after VIT discontinuation...
December 16, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29205109/new-treatments-for-allergy-advances-in-peptide-immunotherapy
#5
David Calzada, Selene Baos, Lucia Cremades, Blanca Olombrada Cardaba
BACKGROUND: Nowadays, allergen-specific immunotherapy (AIT) is the only treatment able to modulate the course of allergic diseases. Although it has been applied for the last 100 years, treatment with whole allergen extracts is not without its drawbacks: AIT can cause local and systemic adverse events and may produce new IgE sensitization against other allergens present in the extract. Furthermore, the lengthy treatment duration (3-5 years), frequent administration, and high cost of treatment are other disadvantages...
November 30, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29202591/venom-immunotherapy-in-patients-with-allergic-reactions-to-insect-stings
#6
Cristoforo Incorvaia, Marina Mauro, Bruna L Gritti, Eleni Makri, Erminia Ridolo
Allergy to Hymenoptera (Apis mellifera, Vespula species, Polistes species, Vespa crabro) venom can be safely and effectively treated by venom immunotherapy (VIT), which in the 40 years since its introduction has been able to prevent reactions to stings, and to treatment as well, though systemic reactions, occasionally severe, are possible. Areas covered: We reviewed the recent literature on VIT by searching in PubMed for the terms "venom immunotherapy" and "Hymenoptera venom immunotherapy" to highlight the current status of VIT and the likely development in the coming years...
December 5, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29171032/immunological-differences-between-insect-venom-allergic-patients-with-and-without-immunotherapy-and-asymptomatically-sensitized-subjects
#7
Lisa Arzt, Danijela Bokanovic, Christoph Schrautzer, Karin Laipold, Christian Möbs, Wolfgang Pfützner, Sereina Annik Herzog, Jutta Vollmann, Norbert Reider, Barbara Bohle, Werner Aberer, Gunter Sturm
BACKGROUND: Currently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist. Our aim was to find reliable serological markers to predict tolerance to bee and vespid stings. METHODS: We included 77 asymptomatically-sensitized subjects, 85 allergic-patients with acute systemic sting reactions, and 61 allergic-patients currently treated with VIT...
November 23, 2017: Allergy
https://www.readbyqxmd.com/read/29166906/anaphylaxis-in-an-emergency-care-setting-a-one-year-prospective-study-in-children-and-adults
#8
Athamaica Ruiz Oropeza, Annmarie Lassen, Susanne Halken, Carsten Bindslev-Jensen, Charlotte G Mortz
BACKGROUND: Current data on anaphylaxis is based on retrospective and register based studies. The objective of this study was to describe the epidemiology of anaphylaxis in a 1 year prospective study at the emergency care setting, Odense University Hospital, Denmark (2013-2014). METHODS: Prospective study at the emergency care setting, Odense University Hospital, Denmark (2013-2014). To identify anaphylaxis cases, records from all patients with clinical suspicion on anaphylaxis or a related diagnosis according to the International Classification of Diseases 10 and from patients treated at the emergency care setting or at prehospital level with adrenaline, antihistamines or glucocorticoids were reviewed daily...
November 22, 2017: Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
https://www.readbyqxmd.com/read/29156294/phospholipase-a1-based-cross-reactivity-among-venoms-of-clinically-relevant-hymenoptera-from-neotropical-and-temperate-regions
#9
Amilcar Perez-Riverol, Luís Gustavo Romani Fernandes, Alexis Musacchio Lasa, José Roberto Aparecido Dos Santos-Pinto, Débora Moitinho Abram, Gabriel Hideki Izuka Moraes, Frederic Jabs, Michaela Miehe, Henning Seismman, Mario Sergio Palma, Ricardo de Lima Zollner, Edzard Spillner, Márcia Regina Brochetto-Braga
Molecular cross-reactivity caused by allergen homology or cross-reactive carbohydrate determinants (CCDs) is a major challenge for diagnosis and immunotherapy of insect venom allergy. Venom phospholipases A1 (PLA1s) are classical, mostly non-glycosylated wasp and ant allergens that provide diagnostic benefit for differentiation of genuine sensitizations from cross-reactivity. As CCD-free molecules, venom PLA1s are not causative for CCD-based cross-reactivity. Little is known however about the protein-based cross-reactivity of PLA1 within vespid species...
November 17, 2017: Molecular Immunology
https://www.readbyqxmd.com/read/29130986/skin-test-reactivity-to-hymenoptera-venom-after-venom-immunotherapy-correlates-inversely-with-the-igg-ige-ratio
#10
Ieva Saulite, Wolfram Hoetzenecker, Emmanuella Guenova, Peter Schmid-Grendelmeier, Martin Glatz
BACKGROUND: Skin test reactivity to hymenoptera venom and venom-specific IgE are important for diagnosing venom allergy and deciding on the appropriate allergen for venom immunotherapy (VIT). Longitudinal data on skin test reactivity during VIT and their correlation with venom-specific immunoglobulin (Ig)E and IgG are scarce. METHODS: We retrospectively analyzed shifts in skin test reactivity and serum levels of venom-specific IgE and IgG in patients allergic to hymenoptera venom before the initiation of VIT with ultrarush therapy and after ≥3 years of VIT...
2017: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/29106324/safety-of-specific-immunotherapy-using-an-ultra-rush-induction-regimen-in-bee-and-wasp-allergy
#11
Andrzej Bożek, Krzysztof Kołodziejczyk
BACKGROUND: Specific allergen immunotherapy to Hymenoptera venom (VIT) is a basic treatment for patients allergic to Hymenoptera venom. The aim of the study was to evaluate the safety of an ultra-rush regimen compared with the rush and conventional protocols. MATERIALS AND METHODS: In 31 patients with an allergy to bee venom and 82 with an allergy to wasp venom, the allergic adverse reactions during VIT were monitored. Patients were selected based on the criteria established by EAACI (European Academy of Allergy and Clinical Immunology) recommendations...
November 6, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29017820/possible-utility-of-the-basophil-activation-test-for-the-analysis-of-mechanisms-involved-in-allergic-transfusion-reactions
#12
REVIEW
Fumiya Hirayama, Kazuta Yasui, Nobuki Matsuyama, Ikue Okamura-Shiki
Allergic transfusion reactions (ATRs) are the most common adverse reactions occurring during transfusion of blood components. Although most reactions are mild and involve cutaneous manifestations, severe ATRs including life-threatening anaphylaxis may also occur. The mechanisms of ATRs are largely unknown because they have not been well studied. One of the reasons for this may be the absence of a standard assay system for investigating these processes. Basophils and/or mast cells are key effector cells in immediate-type allergic reactions...
September 19, 2017: Transfusion Medicine Reviews
https://www.readbyqxmd.com/read/28950273/venom-immunotherapy-in-high-risk-patients-the-advantage-of-the-rush-build-up-protocol
#13
Yossi Rosman, Ronit Confino-Cohen, Arnon Goldberg
BACKGROUND: Venom immunotherapy (VIT) is considered to be the gold standard treatment for patients with hymenoptera venom allergy. This treatment induces systemic reactions (SR) in a significant number of patients. OBJECTIVE: To evaluate the outcome of VIT in patients with known risk factors for VIT-induced SR and to compare rush VIT (RVIT) and conventional VIT (CVIT). METHODS: All of the patients who received VIT and had at least one of the following risk factors were included: current cardiovascular disease, uncontrolled asthma, high basal serum tryptase, current treatment with β-blockers or angiotensin-converting enzyme inhibitors, and age >70 or <5 years...
2017: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/28932384/erratum-to-allergen-immunotherapy-for-insect-venom-allergy-protocol-for-a-systematic-review
#14
Sangeeta Dhami, Ulugbek Nurmatov, Eva-Maria Varga, Gunter Sturm, Antonella Muraro, Cezmi A Akdis, Darío Antolín-Amérigo, M Beatrice Bilò, Danijela Bokanovic, Moises A Calderon, Ewa Cichocka-Jarosz, Joanna N G Oude Elberink, Radoslaw Gawlik, Thilo Jakob, Mitja Kosnik, Joanna Lange, Ervin Mingomataj, Dimitris I Mitsias, Holger Mosbech, Oliver Pfaar, Constantinos Pitsios, Valerio Pravettoni, Graham Roberts, Franziska Ruëff, Betül Ayşe Sin, Aziz Sheikh
[This corrects the article DOI: 10.1186/s13601-016-0095-x.].
2017: Clinical and Translational Allergy
https://www.readbyqxmd.com/read/28916424/predictors-of-epinephrine-dispensing-and-allergy-follow-up-after-emergency-department-visit-for-anaphylaxis
#15
Megan Motosue, M Fernanda Bellolio, Holly K Van Houten, Nilay D Shah, Ronna L Campbell
BACKGROUND: National guidelines recommend that patients with anaphylaxis be prescribed an epinephrine auto-injector (EAI) and referred to an allergy/immunology (A/I) specialist. OBJECTIVE: To evaluate guideline concordance and identify predictors of EAI dispensing and A/I follow-up in patients with anaphylaxis treated in the emergency department (ED). METHODS: We identified patients seen in the ED for anaphylaxis from 2010 through 2014 from an administrative claims database using an expanded International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code algorithm...
September 12, 2017: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/28902950/pre-emptive-evaluation-of-venom-allergy-in-a-patient-with-systemic-mastocytosis
#16
Theo Gülen, Cem Akin
No abstract text is available yet for this article.
September 13, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/28888247/fatal-anaphylaxis-mortality-rate-and-risk-factors
#17
Paul J Turner, Elina Jerschow, Thisanayagam Umasunthar, Robert Lin, Dianne E Campbell, Robert J Boyle
Up to 5% of the US population has suffered anaphylaxis. Fatal outcome is rare, such that even for people with known venom or food allergy, fatal anaphylaxis constitutes less than 1% of total mortality risk. The incidence of fatal anaphylaxis has not increased in line with hospital admissions for anaphylaxis. Fatal drug anaphylaxis may be increasing, but rates of fatal anaphylaxis to venom and food are stable. Risk factors for fatal anaphylaxis vary according to cause. For fatal drug anaphylaxis, previous cardiovascular morbidity and older age are risk factors, with beta-lactam antibiotics, general anesthetic agents, and radiocontrast injections the commonest triggers...
September 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28881055/individual-healthcare-plan-for-allergic-children-at-school-lessons-from-a-2015-2016-school-year-survey
#18
Guillaume Pouessel, Stépanie Lejeune, Marie-Pierre Dupond, Annie Renard, Camille Fallot, Antoine Deschildre
BACKGROUND: The individual healthcare plan (IHP) was implemented in schools in France in 2003 to improve management of allergic children. Our objectives were to assess the practical aspects of IHP (excluding asthma) and allergic reactions occurring at school. METHODS: Prospective study conducted in the North Department (France) during the 2015/2016 school year. Two questionnaires were developed: one for the school doctors (n = 67) and one for the school principals (n = 2372)...
September 7, 2017: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/28837089/heterologous-expression-purification-and-immunoreactivity-of-the-antigen-5-from-polybia-paulista-wasp-venom
#19
Murilo Luiz Bazon, Amilcar Perez-Riverol, José Roberto Aparecido Dos Santos-Pinto, Luis Gustavo Romani Fernandes, Alexis Musacchio Lasa, Débora Laís Justo-Jacomini, Mario Sergio Palma, Ricardo de Lima Zollner, Márcia Regina Brochetto-Braga
Polybia paulista (Hymenoptera: Vespidae) is responsible for a high number of sting accidents and anaphylaxis events in Southeast Brazil, Argentina and Paraguay. The specific detection of allergy to the venom of this wasp is often hampered by the lack of recombinant allergens currently available for molecular diagnosis. Antigen 5 (~23 kDa) from P. paulista venom (Poly p 5) is a highly abundant and glycosylated allergenic protein that could be used for development of component-resolved diagnosis (CRD). Here, we describe the cloning and heterologous expression of the antigen 5 (rPoly p 5) from P...
August 24, 2017: Toxins
https://www.readbyqxmd.com/read/28802075/overcoming-severe-adverse-reactions-to-venom-immunotherapy-by-using-anti-ige-antibodies-in-combination-with-a-high-maintenance-dose
#20
Eva Stretz, Eva Maria Oppel, Räwer Helen-Caroline, René Chatelain, Sebastian Mastnik, Bernhard Przybilla, Franziska Ruëff
BACKGROUND: An omalizumab treatment and a high maintenance venom dose may both help to prevent recurrent systemic allergic reactions (SAR) to venom immunotherapy (VIT). The effectiveness of this combination therapy, however, is unclear. OBJECTIVE: We wanted to explore the possibility whether a temporary treatment with the anti-IgE antibody omalizumab, combined with a VIT using an elevated maintenance dose of >100 μg venom may establish a permanent tolerance of maintenance VIT...
August 12, 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
keyword
keyword
77715
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"